Epithelioid Hemangioendothelioma and Epithelioid Hemangioma: Pazopanib as a Potential Salvage Therapy

Abstract

Epithelioid hemangioma (EH) and epithelioid hemangioendothelioma (EHE) are both rare vascular tumors. EH tumors are often benign while EHE tumors have moderate malignant potential. Here, we present three unique cases at Soroka Medical Center, two featuring EH of the bone and one presenting EHE of the mediastinum. Each case demonstrates distinct treatment challenges due to the rarity of both diseases and lack of established guidelines. We propose three treatment approaches including pazopanib for salvage therapy of EH of the bone and minimally invasive surgical resection which in these cases lead to complete symptom relief and tumor stabilization upheld over time with close follow-up.

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in a Rare Case of Epithelioid Hemangioendothelioma – A Diagnostic Challenge

“…Treatment options reported in literature include chemotherapy (carboplatin and paclitaxel), bevacizumab (VEGF inhibitor), radiation therapy, and pazopanib (tyrosine kinase inhibitor). [ 1 , 7 , 13 , 14 ] Given the propensity of EHE patients to present with multiple organ involvement rather than a solitary organ, imaging with 18F-FDG PET/CT seems a better alternative in comparison to region-specific conventional imaging techniques such as CT or MRI. An added advantage of whole-body imaging with PET/CT in EHE patients is to assess posttreatment response.…”